Recovery Peptides
BPC-157
Research Grade≥99% PurityLyophilized
Body Protection Compound 157, studied for cytoprotective mechanisms in connective tissue research.
Dosage
$45.00
Quantity
Bundle & Save
We accept
Certificate of Analysis
Third Party Tested by Freedom Diagnostics
Frequently Bought Together
Bacteriostatic Water
10 ml
$10.00
GLP-3 RT
10 mg
$110.00
GLP-2 TZ
10 mg
$85.00
NAD+
500 mg
$70.00
GHK-Cu
50 mg
$65.00
Melanotan II
10 mg
$55.00
Tesamorelin
10 mg
$85.00
TB-500
10 mg
$45.00
MOTS-c
10 mg
$75.00
Research Summary
BPC-157
Published research data and clinical observations
🔬
Research Phase
35 preclinical + 1 clinical study
💉
Administration
Stable in gastric acid
🧬
Key Pathway
Angiogenesis & NO system
📄
Publications
Peer-reviewed papers
🐁
Subjects Studied
Across multiple models
What Makes BPC-157 Different?
The Science, Simplified
Three Pathways, One Peptide
BPC-157 doesn't rely on a single mechanism. It simultaneously activates three distinct repair pathways — angiogenesis, cell migration, and nitric oxide signaling — which is why it shows effects across so many tissue types in preclinical research.
VEGF
Primary
VEGFR2-Akt-eNOS
Angiogenesis pathway
New blood vessel formation
Oxygen delivery to injuries
Tissue repair acceleration
FAK
Secondary
FAK-Paxillin Pathway
Cell migration signaling
Tendon fibroblast outgrowth
Cell survival under stress
Wound closure acceleration
NO
Modulator
Nitric Oxide System
Vasodilation & blood flow
Anti-inflammatory effects
Dopamine system balance
GI mucosal protection
WHY ORAL STABILITY MATTERS
Survives Stomach Acid
Most peptides are destroyed by gastric acid within minutes. BPC-157 is derived from human gastric juice and remains structurally intact in the stomach:
Can be administered orally or by injection — the only recovery peptide with confirmed oral bioavailability in preclinical models.
BPC-157Oral + SC (acid stable)
TB-500SC / IP only
GHK-CuTopical / SC only
What Researchers Observed
42-61%
Faster re-epithelialization vs controls
Chang et al. tendon outgrowth model (2011)
85%
92%
88%
75%
Key Milestones Achieved
90%
CD34/FVIII immunohistochemistry
78%
Confirmed via fibroblast culture
58%
7/12 patients in retrospective study
For context:A 2025 systematic review (PMC12313605) across 36 studies found BPC-157 consistently promoted tendon, ligament, and muscle healing in preclinical models. Only 1 clinical study exists: a retrospective analysis showing 7 of 12 patients with chronic knee pain reported relief >6 months after intra-articular BPC-157.
Compound Information
Technical specifications
❄️ Storage Requirements
Stability Information
Avoid freeze/thaw cyclesProtect from lightKeep refrigerated
Lyophilized (powder)
-20°C · 24+ months
Reconstituted
2-8°C · ~30 days
📋 Development Status
Where It Stands
PreclinicalResearch Use Only
DeveloperAcademic research
Trial ProgramMultiple preclinical
Results36 studies reviewed (2025)
This page summarizes published research for informational purposes only. These products are sold exclusively as research chemicals and are not intended for human consumption. Always consult peer-reviewed literature for complete study details.
Your Cart
Your cart is empty